A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer

Stopped early · Phase 1/Phase 2

Conditions studied: Non-small-cell Lung Cancer

In brief

This is a Phase I-II study designed to investigate nimotuzumab (TheraCIM h-R3) in combination with external radiation in patients with non-small cell lung cancer. The purpose of the Phase I portion of the study is to evaluate the safety and feasibility of the administration of nimotuzumab with palliative radiation in patients who are unsuitable for radical therapy and to select the optimal dose for the Phase II component of the study. The primary objective for the Phase II portion of the study is to examine the efficacy of this combination treatment. The Phase I component of this study has been completed. The Phase II is now closed to recruitment.

Key facts

Study ID
NCT00369447
Run by
YM BioSciences
People needed
52
Starts
2009-03-01
Expected to finish
2011-07-01
Last updated by the study team
2011-07-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.